Table 4 Baseline clinical profiles and responses after CHP-NY-ESO-1 vaccinations
100 μg | 200 μg | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
pt No. | Response to previous therapies (duration time, weeks) | *sum of tumor diameters (mm) | Tumor response (BOR) | Time-to-progression (weeks) | Survival (weeks) | pt No. | Response to previous therapies (duration time, weeks) | *sum of tumor diameters (mm) | Tumor response (BOR) | Time-to-progression (weeks) | Survival (weeks) |
100-01 | PR (4) | NA | PD | 6 | 31 | 200-01 | PR (29) | 24 | SD | 17 | 70 |
100-02 | SD | 53 | NE | 4 | 6 | 200-02 | NE | 25 | SD | 18 | 33 |
100-03 | NE | 144 | NE | 4 | 6 | 200-03 | PR (32) | 55 | PD | 6 | 37 |
100-04 | PD | 182 | PD | 5 | 17 | 200-04 | PR (30) | NA | PD | 6 | 50 |
100-05 | CR (38) | 101 | NE | 4 | 4 | 200-05 | PR (32) | NA | PD | 6 | 72 |
100-06 | SD | 69 | PD | 6 | 31 | 200-06 | NE | 32 | SD | 18 | 54 |
100-07 | CR (15) | 78 | PD | 6 | 29 | 200-07 | NE | 205 | NE | 6 | 8 |
100-08 | NE | 39 | SD | 18 | 23 | 200-08 | PR (12) | 16 | SD | 11 | 33 |
100-09 | SD | 18 | PD | 6 | 8 | 200-09 | CR (96) | 88 | PD | 6 | 45 |
100-10 | CR (24) | NA | SD | 11 | 60 | 200-10 | SD | NA | SD | 12 | 48 |
100-11 | SD | 31 | SD | 12 | 20 | 200-11 | SD | NA | NE | 6 | 12 |
100-12 | PR (9) | NA | NE | 16 | 28 | 200-12 | SD | NA | SD | 12 | 33 |
100-13 | PR (16) | NA | NE | 52 | 59 | ||||||